Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry

• Published in: bioRxiv
• Main Authors: Park, Young-Jun, De Marco, Anna, Starr, Tyler N, Liu, Zhuoming, Pinto, Dora, Walls, Alexandra C, Zatta, Fabrizia, Zepeda, Samantha K, Bowen, John, Sprouse, Kaitlin S, Joshi, Anshu, Giurdanella, Martina, Guarino, Barbara, Noack, Julia, Abdelnabi, Rana, Foo, Shi-Yan Caroline, Lempp, Florian A, Benigni, Fabio, Snell, Gyorgy, Neyts, Johan, Whelan, Sean Pj, Virgin, Herbert W, Bloom, Jesse D, Corti, Davide, Pizzuto, Matteo Samuele, Veesler, David
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 14.10.2021; Cold Spring Harbor Laboratory
• Edition: 1.1
• Subjects: ACE2; Angiotensin-converting enzyme 2; Antibodies; Binding sites; Biotechnology; Epitopes; Immunology; Mimicry; Monoclonal antibodies; Patent applications; Severe acute respiratory syndrome coronavirus 2; Structure-function relationships
• ISSN: 2692-8205; 2692-8205
• DOI: 10.1101/2021.10.13.464254

Understanding broadly neutralizing sarbecovirus antibody responses is key to developing countermeasures effective against SARS-CoV-2 variants and future spillovers of other sarbecoviruses. Here we describe the isolation and characterization of a human monoclonal antibody, designated S2K146, broadly neutralizing viruses belonging to all three sarbecovirus clades known to utilize ACE2 as entry receptor and protecting therapeutically against SARS-CoV-2 beta challenge in hamsters. Structural and functional studies show that most of the S2K146 epitope residues are shared with the ACE2 binding site and that the antibody inhibits receptor attachment competitively. Viral passaging experiments underscore an unusually high barrier for emergence of escape mutants making it an ideal candidate for clinical development. These findings unveil a key site of vulnerability for the development of a next generation of vaccines eliciting broad sarbecovirus immunity.